AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Davenport & Co LLC Reduces Enovis Corp Holdings Amid Mixed Performance Indicators
ByAinvest
Sunday, Aug 17, 2025 6:07 am ET1min read
Davenport & Co LLC reduced its Enovis Corp holdings by 86,865 shares, impacting its portfolio by -0.01%. The firm now holds 2,756,270 shares of Enovis Corp, with a 4.83% ratio of the firm's holdings in the stock. The transaction was executed at $26.8 per share. Enovis Corp has a market capitalization of $1.69 billion and generates most revenue from the Prevention & Recovery segment. The company has experienced a 10.26% gain since the transaction but a -33.3% year-to-date price change.
Davenport & Co LLC recently reduced its holdings in Enovis Corp by 86,865 shares, impacting its portfolio by -0.01%. The firm now holds 2,756,270 shares of Enovis Corp, representing a 4.83% ratio of its total holdings in the stock. The transaction was executed at $26.8 per share [1].Enovis Corp, a medical technology company, operates through the Prevention & Recovery and Reconstructive segments. The Prevention & Recovery segment focuses on orthopedic solutions and recovery sciences, while the Reconstructive segment handles surgical implants and productivity tools [2].
The company reported strong earnings for the second quarter of 2025. Revenue reached $564.5 million, exceeding analyst estimates by 7.5% year-on-year growth and a 2% beat. Adjusted EPS was $0.79, surpassing estimates by 9.9% and a 2.9% beat. Adjusted EBITDA was $97.2 million, up 17.2% margin and a 2.9% beat. The company lifted its full-year revenue and Adjusted EPS guidance, with revenue expected to reach $2.26 billion and Adjusted EPS to $3.13 [1].
The stock has experienced a 10.26% gain since the transaction but a -33.3% year-to-date price change. Enovis Corp currently trades at $29.59, up from $25.75 just before the earnings announcement [1].
Analysts have highlighted several key topics during Enovis's Q2 earnings call, including the impact of new product launches, the transparency of adjusted EBITDA metrics, and the company's strategy to maintain leadership in the competitive shoulder market [1].
References:
[1] https://finance.yahoo.com/news/top-5-analyst-questions-enovis-053451864.html
[2] https://www.marketbeat.com/stocks/NYSE/ENOV/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet